Bisintercalating Threading Diacridines: Relationships between DNA Binding, Cytotoxicity, and Cell Cycle Arrest

Journal of Medicinal Chemistry

Volumn 46, Issue 26, 2003, Pages 5790-5802

  Wakelin, Laurence P G ^a   Bu, Xianyong ^a   Eleftheriou, Alexandra ^a   Parmar, Alpesh ^a   Hayek, Charbel ^a   Stewart, Bernard W ^a,b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Public Health Unit   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

9 ANILINOACRIDINE DERIVATIVE; ACRIDINE DERIVATIVE; AMIDE; AMSACRINE; AMSACRINE 4 CARBOXAMIDE; ANTHRACYCLINE DERIVATIVE; ANTHRAQUINONE DERIVATIVE; BIS(9 AMINOACRIDINE 4 CARBOXAMIDE); CAMPTOTHECIN; CHROMOMYCIN; DACTINOMYCIN; DAUNORUBICIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ECHINOMYCIN; GUANINE; INTERCALATING AGENT; MITOXANTRONE; MORPHOLINE DERIVATIVE; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE; NOGALAMYCIN; PIPERAZINE DERIVATIVE; POLYAMINE; UNCLASSIFIED DRUG;

ARTICLE; CELL CYCLE; CELL CYCLE G2 PHASE; CONTROLLED STUDY; CYTOTOXICITY; DNA BINDING; DNA SUPERCOILING; HUMAN; HUMAN CELL; HYDROGEN BOND; IC 50; LEUKEMIA CELL; TRANSCRIPTION REGULATION;

ACRIDINES; ANTINEOPLASTIC AGENTS; CELL CYCLE; CELL DEATH; CELL DIVISION; CELL LINE, TUMOR; DNA; DNA, SUPERHELICAL; ELECTROPHORESIS, AGAR GEL; FLOW CYTOMETRY; G2 PHASE; GUANINE; HUMANS; HYDROGEN BONDING; INTERCALATING AGENTS; KINETICS; MITOSIS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0347627153     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030253d     Document Type: Article

References (55)

1. Liu, L. F. DNA topoisomerase poisons as antitumor drugs. Annu. Rev. Biochem. 1989, 58, 351-75.
2. Malonne, H.; Atassi, G. DNA topoisomerase targeting drugs: Mechanisms of action and perspectives. Anticancer Drugs 1997, 8, 811-22.
3. Kellner, U.; Sehested, M.; Jensen, P. B.; Gieseler, F.; Rudolph, P. Culprit and victim - DNA topoisomerase II. Lancet Oncol. 2002, 3, 235-43.
4. Verweij, J.; den Hartigh, J.; Pinedo, H. M. Antitumor antibiotics. In Cancer Chemotherapy: Principles and Practice; Chabner, B. A, Collins, J. M., Eds.; J. B. Lippincott Co.: Philidelphia, 1990; pp 382-96.
5. Denny, W. A.; Roos, I. A. G.; Wakelin, L. P. G. Interrelations between antitumour activity, DNA breakage, and DNA binding kinetics for 9-aminoacridinecarboxamide antitumor agents. Anti-Cancer Drug Des. 1986, 1, 141-7.
6. Bridewell, D. J.; Finlay, G. J.; Baguley, B. C. Topoisomerase I/II selectivity among derivatives of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide (DACA). Anti-Cancer Drug Des. 2001, 16, 317-24.
7. Caponigro, F.; Dittrich, C.; Sorensen, J. B.; Schellens, J. H.; Duffaud, F.; Paz Ares, L.; Lacombe, D.; de Balincourt, C.; Fumoleau, P. Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer. Eur. J. Cancer 2002, 38, 70-4.
8. Muller, W.; Crothers, D. M. Studies of the binding of actinomycin and related compounds to DNA. J. Mol. Biol. 1968, 35, 251-90.
9. Waring, M. J.; Wakelin, L. P. G. Echinomycin: A bifunctional intercalating antibiotic. Nature 1974, 25, 653-657.
10. Searle, M. S.; Hall, J. G.; Denny, W. A.; Wakelin, L. P. G. NMR studies of the interaction of the antibiotic nogalamycin with the hexadeoxyribonucleotide duplex d(5′-GCATGC)2. Biochemistry 1988, 27, 4340-4349.
11. Farber, S.; D'Angio, G.; Evans, A.; Mitus, A. Clinical studies of actinomycin D with special reference to Wilms' tumor in children. J. Urol. 2002, 168, 2560-2.
12. Gradishar, W. J.; Vogelzang, N. J.; Kilton, L. J.; Leibach, S. J.; Rademaker, A. W.; French, S.; Benson, A. B., III. A phase II clinical trial of echinomycin in metastatic soft tissue sarcoma. An Illinois Cancer Center Study. Invest. New Drugs 1995, 13, 171-4.
13. 2 and the anticancer drug actinomycin D. J. Mol. Biol. 1992, 225, 445-56.
14. Ughetto, G.; Wang, A. H.; Quigley, G. J.; van der Marel, G. A.; van Boom, J. H.; Rich, A. A. Comparison of the structure of echinomycin and triostin A complexed to a DNA fragment. Nucleic Acids Res. 1985, 13, 2305-23.
15. Fox, K. R.; Brassett, C.; Waring, M. J. Kinetics of dissociation of nogalamycin from DNA: Comparison with other anthracycline antibiotics. Biochim. Biophys. Acta 1985, 840, 383-92.
16. Fox, K. R.; Wakelin, L. P. G.; Waring, M. J. Kinetics of the interaction between echinomycin and DNA. Biochemistry 1981, 20, 5768-5779.
17. Wakelin, L. P. G.; Atwell, G. J.; Rewcastle, G. W.; Denny, W. A. Relationships between DNA binding kinetics and biological activity for the 9-aminoacridine-4-carboxamide class of antitumour agent. J. Med. Chem. 1987, 30, 855-861.
18. Denny, W. A.; Wakelin, L. P. G. Kinetics of the binding of mitoxantrone, ametantrone and analogues to DNA: Relationship to binding mode and antitumour activity. Anti-Cancer Drug Des. 1990, 5, 189-200.
19. Wakelin, L. P. G.; Adams, A.; Denny, W. A. Kinetic studies of the binding of acridinecarboxamide topoisomerase poisons to DNA: Implications for the mode of binding of ligands with uncharged chromophores. J. Med. Chem. 2002. 45, 894-901.
20. Wakelin, L. P. G.; Chetcuti, P.; Denny, W. A. Kinetic and equilibrium studies of amsacrine-4-carboxamides: A class of asymmetrical DNA intercalating agent which must bind by threading through the DNA helix. J. Med. Chem. 1990, 33, 2039-2044.
21. 2. Biochemistry 1999, 38, 9221-9233.
22. 2: Implications for Structure Activity Relationships of Acridinecarboxamide Topoisomerase Poisons. Nucleic Acids Res. 2002, 30, 719-725.
23. Denny, W. A. DNA-intercalating ligands as anti-cancer drugs: Prospects for future design. Anti-Cancer Drug Des. 1989, 4, 241-263.
24. Leng, F.; Priebe, W.; Chaires, J. B. Ultratight DNA binding of a new bisintercalating anthracycline antibiotic. Biochemistry 1998, 37, 1743-53.
25. Murr, M. M.; Harting, M. T.; Guelev, V.; Ren, J.; Chaires, J. B.; Iverson, B. L. An octakis-intercalating molecule. Bioorg. Med. Chem. 2001, 9, 1141-8.
26. Miller, C. T.; Weragoda, R.; Izbicka, E.; Iverson, B. L. The synthesis and screening of 1,4,5,8-naphthalenetetracarboxylic diimide-peptide conjugates with antibacterial activity. Bioorg. Med. Chem. 2001, 9, 2015-24.
27. Wakelin, L. P. G. Polyfunctional DNA intercalating agents. Med. Res. Rev. 1986, 6, 275-340.
28. Chow, K.-C.; Ross, W. E. Topoisomerase-specific drug sensitivity in relation in cell cycle progression. Mol. Cell. Biol. 1987, 7, 3119-23.
29. Sleiman, R. J.; Catchpoole, D. R.; Stewart, B. W. Drug-induced death of leukaemic cells after G2/M arrest: Higher order DNA fragmentation as an indicator of mechanism. Br. J. Cancer 1998, 77, 40-50.
30. Kohn, K. W.; Jackman, J.; O'Connor, P. M. Cell cycle control and cancer chemotherapy. J. Cell Biol. 1994, 54, 440-52.
31. Hannun, Y. A. Apoptosis and the dilemma of cancer chemotherapy. Blood 1997, 89, 1845-53.
32. Sleiman, R. J.; Stewart, B. W. Early caspase activation in leukemic cells subject to etoposide-induced G2-M arrest: Evidence of commitment to apoptosis rather than mitotic cell death. Clin. Cancer Res. 2000, 6, 3756-65.
33. Del Bino, G.; Skierski, J. S.; Darzynkiewicz, Z. Diverse effects of camptothecin, an inhibitor of topoisomerase I, on the cell cycle of lymphocytic (L1210, MOLT-4) and myelogenous (HL-60, KG1) leukemic cells. Cancer Res. 1990, 50, 5746-50.
34. Rene, B.; Fosse, P.; Khelifa, T.; Jacquemin-Sablon, A.; Bailly, C. Cytotoxicity and interaction of amsacrine derivatives with topoisomerase II: Role of the 1′ substitute on the aniline nucleus. Bull. Cancer 1997, 84, 941-8.
35. Arlin, Z. A. Mitoxantrone and amsacrine: Two important agents for the treatment of acute myelogenous leukemia (AML) and acute lymphoblastic leukemia (ALL). Bone Marrow Transplant 1989, 4 Suppl 1, 57-9.
36. Rewcastle, G. W.; Denny, W. A. The synthesis of substituted 9-oxoacridan-4-carboxylic acids; Part 2. The use of 2-Iodoisophthalic acid in the Jourdan-Ullmann Reaction. Synthesis 1985, 217-220.
37. Adams, A.; Guss, J. M.; Collyer, C. A.; Denny, W. A.; Prakash, A. S.; Wakelin, L. P. G. Acridinecarboxamide topoisomerase poisons: Structural and kinetic studies of the DNA complexes of 5-substituted 9-amino-(N-(2-dimethylamino)ethyl)-acridine-4-carboxamides. Mol. Pharmacol. 2000, 58, 649-658.
38. D'Rozario, A. P.; Greig, D. J.; Hudson, R. F.; Williams, A.; Stepwise Proton Transfer in the Acid-catalysed Hydrolysis of 3,1-Benzoxazin-4-ones: Electrostatic or Hydrogen-bond Stabilisation of the Conjugate Acid. J. Chem. Soc., Perkin Trans. 2 1981, 590-596.
39. Sumpter, W. C.; Jones, W. F. The Nitration of Isatin. J. Am. Chem. Soc. 1943, 65, 1802-1803.
40. Deady, L. W.; Kaye, A. J.; Finlay, G. J.; Baguley, B. C.; Denny, W. A. Synthesis and antitumor properties of N-[2-(dimethylami-no)ethyl]carboxamide derivatives of fused tetracyclic quinolines and quinoxalines: A new class of putative topoisomerase inhibitors. J. Med. Chem. 1997, 40, 2040-6.
41. Atwell, G. J.; Cain, B. F.; Baguley, B. C.; Finlay, G. J.; Denny, W. A. Potential antitumor agents. 43. Synthesis and biological activity of dibasic 9-aminoacridine-4-carboxamides, a new class of antitumor agent. J. Med. Chem. 1984, 27, 1481-85.
42. Adelson, D. E.; Polland, C. B. Derivatives of Piperazine. IV. Reactions with Derivatives of Monochloroacetic Acid. J. Am. Chem. Soc. 1935, 57, 1280-81.
43. 2- = anion of N,N′ -bis(2-((o-hydroxybenzhydrylidene)-amino)-ethyl)piperazine). Inorg. Chem. 1984, 23, 2542-47.
44. Denny, W. A.; Atwell, G. J.; Baguley, B. C.; Wakelin, L. P. G. Potential antitumour agents. Part 44. Synthesis and antitumour activity of new classes of diacridines: The importance of linker chain rigidity for DNA-binding kinetics and antitumor activity. J. Med. Chem. 1985, 28, 1568-1574.
45. Nielsen, P. E.; Zhen, W. P.; Henriksen, U.; Buchardt, O. Sequence-influenced interactions of oligoacridines with DNA detected by retarded gel electrophoretic migrations. Biochemistry 1988, 27, 67-73.
46. Chen, S. F.; Bhenrens, D. L.; Czerniak, P. M.; Dexter, D. L.; Dusak, B. J.; Fredericks, J. R.; Gale, K. C.; Gross, J. L.; Krishenbaum, M. R.; McRipley, L. M.; Patten, A. D.; Perella, F. W.; Seltz, S. P.; Stafford, M. P.; Sun, J. H. ; Sun, T.; Wuonola, M. A.; von Hoff, D. D. XB596, a promising bis-naphthalimide anti-cancer agent. Anticancer Drugs 1993, 4, 447-457.
47. Fritzsche, H.; Triebel, H.; Chaires, J. B.; Dattagupta, N.; Crothers, D. M. Studies on the interaction of anthracycline antibiotics and deoxyribonucleic acid: Geometry of intercalation of iremycin and daunomycin. Biochemistry 1982, 21, 3940-3946.
48. Bauer, W. R. Structure and reactions of closed duplex DNA. Annu. Rev. Biophys. Bioeng. 1978, 7, 287-313.
49. Gao, X. L.; Mirau, P.; Patel, D. J. Structure refinement of the chromomycin dimer-DNA oligomer complex in solution. J. Mol. Biol. 1992, 223, 259-79.
50. Blagosklonny, M. V.; Pardee, A. B. Exploiting cancer cell cycling for selective protection of normal cells. Cancer Res. 2001, 61, 4301-5.
51. Solary, E.; Droin, N.; Sordet, O.; Rebe, C.; Filomenko, R.; Wotawa, A.; Plenchette, S.; Ducoroy, P. Cell death pathways as targets for anticancer drugs. In Anticancer Drug Development; Baguley, B. C., Kerr, D. J., Eds.; Academic Press: San Diego, 2002; pp 55-76.
52. Waldmann, H. Isatincarboxylic acid. J. Prakt. Chem. 1937, 147, 338-43.
53. Lown, J. W.; Morgan, A. R.; Yen, S. F.; Wang, Y. H.; Wilson, W. D. Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxy-ribonucleic acids. Biochemistry 1985, 24, 4028-35.
54. Waring, M. J. DNA-binding characteristics of acridinylmethane-sulphonanilide drugs: Comparison with antitumour properties. Eur. J. Cancer 1976, 12, 995-1001.
55. Waring, M. J. Variation of the supercoils in closed circular DNA by binding of antibiotics and drugs: Evidence for molecular models involving intercalation. J. Mol. Biol. 1970, 54, 247-279.